Company Dossier · Health Care
Doximity
- Russell 1000
- MidCap 400
What Doximity is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $0.66 billion, up 12% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2025: $0.29 billion, up 71% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2025: $0.00 billion.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to March 31, 2026: $0.43 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 6, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 1 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed May 19, 2026): 1 risk factor added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $0.5 million on the open market.SEC Form 4
- 358 institutional managers reported a position at June 30, 2026 (−65 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 3 (3 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Doximity yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Doximity, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralDoximity (DOCS) Director Yang Watkin Phoebe L. Sells 1,290 Shares
gurufocus.com · via Marketaux · Oct 2, 2026
- Neutral
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Sep 2, 20268-KShareholder vote resultsItem 5.07
- May 19, 202610-KAnnual report (10-K)1 risk factors added, 0 removed
- May 13, 20268-KDirector or officer changeItem 5.02
- May 12, 2026Patent
- Apr 17, 20268-KDirector or officer changeItem 5.02
- Mar 3, 2026Patent
- Feb 17, 2026Patent
- Feb 5, 20268-KDirector or officer changeItem 5.02
- Nov 20, 2025Trademark
- Sep 2, 20258-KShareholder vote resultsItem 5.07
- Aug 15, 20258-KDirector or officer changeItem 5.02
- Jun 13, 20258-KDirector or officer changeItem 5.02
- May 20, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Oct 8, 2024Patent
- Aug 27, 2024Patent
- May 23, 202410-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Arrowhead Pharmaceuticals ARWR | $0.7B | −$0.1B | Jun 30, 2026 |
| BridgeBio Pharma BBIO | $0.7B | −$0.4B | Jun 30, 2026 |
| Axsome Therapeutics AXSM | $0.8B | −$0.1B | Jun 30, 2026 |
| Repligen RGEN | $0.8B | $0.1B | Jun 30, 2026 |
| Corcept Therapeutics CORT | $0.8B | $0.1B | Jun 30, 2026 |
| Ionis Pharmaceuticals IONS | $0.9B | −$0.6B | Jun 30, 2026 |
| Caris Life Sciences CAI | $1.0B | $0.1B | Jun 30, 2026 |
| Krystal Biotech KRYS | $0.4B | $0.3B | Jun 30, 2026 |